Location History:
- San Diego, CA (US) (1993)
- Suginami-Ku, JP (1997)
Company Filing History:
Years Active: 1993-1997
Title: Seiji Isonishi: Innovator in Cancer Treatment
Introduction
Seiji Isonishi is a prominent inventor based in San Diego, CA, known for his significant contributions to cancer treatment. He has been instrumental in developing methods that enhance the efficacy of cytotoxic agents used in cancer therapies. With a total of 2 patents, his work has the potential to improve treatment outcomes for patients suffering from various types of cancer.
Latest Patents
Isonishi's latest patents include innovative methods for treating cancer. One patent focuses on the use of Taxol and epidermal growth factor to enhance treatment for ovarian cancer. This invention outlines a method for sensitizing cancer cells derived from different tissues to various cytotoxic agents, thereby augmenting their sensitivity. The approach involves administering a sensitizing agent either prior to or concurrently with a cytotoxic agent, providing a new avenue for treating cancer and other cell proliferative diseases.
Another significant patent by Isonishi enhances the efficacy of anti-neoplastic drugs using epidermal growth factor (EGF). This invention also details a method for sensitizing cancer cells to cisplatin and other cytotoxic agents, improving their responsiveness to treatment. The dual approach of using sensitizing agents alongside cytotoxic agents represents a promising strategy in cancer therapy.
Career Highlights
Seiji Isonishi is affiliated with the University of California, where he continues to advance research in cancer treatment. His work has garnered attention for its innovative approach to enhancing the effectiveness of existing cancer therapies.
Collaborations
Isonishi has collaborated with notable colleagues in the field, including Stephen B Howell and Randolph D Christen. These partnerships have contributed to the development of his groundbreaking patents and research initiatives.
Conclusion
Seiji Isonishi's contributions to cancer treatment through his innovative patents highlight the importance of research in improving patient outcomes. His work exemplifies the potential of combining sensitizing agents with cytotoxic treatments to enhance therapeutic efficacy.